Author Archives: Emma Day

MARAC Encourages Clinical Research Studies

The Sickle Cell Disease Association of America (SCDAA) Medical and Research Advisory Committee (MARAC) believes that progress in sickle cell disease (SCD) is tied to clinical trials and comprehensive care. For this reason, we encourage individuals with SCD to consider participating in research. It’s because thousands of courageous children and adults with sickle cell disease signed up for research that we have improved survival, developed new medicines and found possible cures. Download the full statement. 

I’ve been invited to be in a clinical trial – what should I know before I sign up?

Here are questions to ask if you are invited to be in a clinical trial. Many of these questions are answered in the informed consent papers – it will be lot to read, and it may be confusing, but it is worthwhile to pay attention and ask questions. You should always get a copy of the consent papers for your records.

  1. What is the purpose of the study?
    There are many types of clinical research studies, but the goal of research is the same – to improve the lives and treatment of individuals with SCD. Some studies involve the use of new drugs. Others look at existing approved therapies to see whether they can be useful for SCD. Sometimes studies are simply questionnaires, X-rays and blood draws. Make sure to ask your physician about the trial’s purpose.
  2. What kind of treatments and tests are involved in the trial?
    As mentioned above, the type and number of treatments differ for each clinical trial. During the trial, a lab technician may need to draw blood or perform an electrocardiogram to ensure that you are reacting well to the treatment. Ask your clinical care team about the treatments and tests you can expect throughout the trial process.
  3. What are the possible risks or side effects of this treatment?
    Side effects vary by trial. You will be closely monitored throughout the clinical trial to ensure that any potential side effects are addressed. It is important to understand all the potential risks or side effects of the treatment before the trial begins.
  4. How will the trial affect my daily life?
    Asking this question will help you be prepared for your upcoming treatment and plan your personal schedule during the trial. Each trial has a different schedule of care. How often do you have to come to the hospital or clinic? Will you have to stay in the hospital during the clinical trial? If so, how often and for how long? How far will you need to travel to take part in the trial?
  5. Do I have to pay for any of the treatments? What costs will my health insurance cover?
    Talking to your health care team, as well as facility staff and your insurance company, will help you answer these questions. Your insurance plan should cover the standard of care or routine care associated with the trial. Research-specific tests and procedures will be paid by the sponsor the trial sponsor. Sometimes transportation assistance is provided and you may receive money to compensate for your time and effort.
  6. Who will oversee my care while I am participating in the trial?
    Your care team will consist of a physician overseeing your participation as well as a team of nurses and research personnel assisting with your treatment and day-to-day care.
  7. What questions should I ask about my other choices?
    What are my other treatment choices, including standard treatments? How does the treatment I would receive in this trial compare with other treatment options? What will happen to my SCD without treatment?
  8. What questions should I ask about my decision process?
    How long do I have to make up my mind about joining this trial? Who can I speak with about questions during and after the trial? Can I talk to who has been in the trial? What if I decide to leave the trial?
  9. What questions should I ask about my rights to privacy?
    How will my health information be kept private? What happens to my data if I decide to leave the trial? Be cautious about clinical research organizations that might want to sell your data to others and/or claim that you will pay less to participate in their trial.
  10. If I benefit from this therapy, will I be allowed to continue receiving it after the trial ends? If I get a placebo, can I switch to the active drug?
    The design of some clinical trials allows patients to continue using the therapy as long as they are benefitting. Clarifying this question with your care team is important.

WATCH: “I participated in clinical trials. I would do it again.” (Video testimony from the National Institutes of  Health)

My friend was asked to participate in a clinical trial, and I wasn’t – why not?

  • Certain kinds of clinical research study new medications with unknown side effects, so they focus on people who are the least likely to be harmed by the new medication. For example, many studies do not accept older people, or individuals who have kidney/liver problems, asthma, are pregnant, heart problems or a high risk for bleeding.
  • If you have not come regularly for sickle cell care or had difficulty taking medications on their prescribed schedule, the research investigators will wonder whether you will follow the rigid schedule of a clinical research study. You may have had valid reasons such as medication side effects or transportation issues. Discuss these barriers with the study team. They may be able to help.
  • Advocate for Ask your doctor(s) whether you are eligible for any clinical research. Some busy doctors simply need a reminder. Others might not have a research study open for enrollment but could refer you to a nearby clinical research group.
  • Go to a specialty sickle cell Clinical research requires a lot of expertise. You might need to find a specialty center with the right level of resources to offer research studies. Consider going at least once a year to an academic, reputable sickle cell center.
  • You might seek out clinical research that does not exclude Surveys, questionnaires and registries can help to change health care systems or set the stage for future research.

How do I find more clinical research opportunities?

  • Ask your doctor(s) whether you are eligible for any clinical research
  • Visit ClinicalTrials.Gov, a government sponsored listing of all approved clinical trials in the U.S. and some abroad.
  • Ask your local SCDAA member organization (or the patients’ organization you belong to) whether they have news about SCD clinical research in your region.
  • Seek studies using clinical research finders for sickle cell on the SCDAA website and oneSCDvoice.com.
  • Many registries study SCD using regular questionnaires. The SCDAA Get Connected Registry is being set up to serve this Registries may also try to relate symptoms with blood tests or genetic tests to lay a foundation for better preventive care in the future.

I’m nervous about participating in clinical research – isn’t it risky?

Clinical research participation today looks very different from the past. Many feel nervous about clinical trials after learning about problems with the Tuskegee syphilis project and the HELA cells from Henrietta Lacks. Know that modern clinical trials are set up with layers of safeguards for patients and opportunities to ask questions. Sponsors of clinical trials keep the interest of patients as a priority. Extra cautions are taken to protect children as research participants. Another new feature of clinical research is the community advisory boards for research studies and SCD research networks. Many individuals with SCD now serve on these boards and you can too.

Can clinical trials replace my regular sickle cell care?

All individuals with SCD should have regular health care appointments, but you should make sure check in with your care team before and after participating in a clinical trial. Comprehensive sickle cell care is available because of those who participated in past research. Honor those who came before you by taking care of yourself.

LEARN MORE:

Questions to ask – adapted from https://www.cancer.gov/about-cancer/treatment/clinical-trials/questions, and from https://sarahcannon.com/blog/entry/7-questions-to-ask-when-considering-a-clinical-trial accessed 9/15/22.

Here are links that describe the features of clinical research studies:

G Puppalwar, M Mourya, G Kadhe, A. Mane. Conducting clinical trials in emerging markets of sub-Saharan Africa: review of guidelines and resources for foreign sponsors. Open Access Journal of Clinical Trials, 7 (2015), pp. 23-34

*MARAC is a diverse group of SCD providers who have volunteered to provide SCDAA and the sickle cell community with trustworthy advice. The primary advice of SCDAA MARAC is directed toward the sickle cell population in the United States, but we recognize frequent implications for other countries and recognize there is wisdom to gain from other countries.

**SCDAA is the leader in promoting and advancing initiatives focused on people affected by sickle cell conditions worldwide. SCDAA is the largest national community-based organization for sickle cell disease. For 50 years SCDAA and its more than 50 member organizations have demonstrated how community-based organizations can work as partners with medical facilities and local and state government agencies to pursue national health care objectives.

Who is watching over the study?

  • IRB (Institutional Review Board) – A special group at a medical center that watches over clinical research safety.
  • DSMB (Data Safety Monitoring Board) – They regularly go over all study data looking for new problems with safety and whether the study should continue.
  • DSMC (Data and Safety Monitoring Committee) – Similar responsibilities as the DSMB.
  • FDA (Food and Drug Administration) – United States government agency that is responsible for drug safety.

Frequently Asked Questions about SCT in Newborn Screening

Many people have questions about sickle cell trait after newborn screening. Dr. Lewis Hsu, SCDAA chief medical officer, answers some of the FAQs below.

Can this test be wrong?

The standard process for newborn screening is that a result showing sickle cell trait will be followed up with another blood test – so two tests will be done. A newborn screening result without any trait will not get a follow up blood test. The newborn screening result is usually correct, and the state labs have quality controls built in. However, issues outside of the lab can make the newborn screening process miss sickle cell trait, for example, if the baby was prematurely born, if the baby got a blood transfusion before the test, if there were problems handling the sample, or if there were errors in entering follow-up contact information.

How do I ask for a confirmation test?

If you would like to be certain about whether your older children have sickle cell trait or not, ask their doctor to order a blood test called “hemoglobin fractionation” or “hemoglobin electrophoresis.” Based on your knowledge that someone in the family has sickle cell trait, this test should be covered by your child’s medical insurance. If you run into barriers for that testing, some local sickle cell organizations (members of SCDAA) offer sickle cell testing free of charge.

Please give me quick information about sickle cell trait.

See this SCDAA brochure with the highlights of information about sickle cell trait – this is exactly what I give my patients, except that it is customized with local resource contact information. The main health concern for sickle cell trait is that the sickle gene can be passed along to the next generation.

Where can I go deeper on what sickle cell trait means for health? I want to know about everything.

The best source for more detailed and up-to-date information about sickle cell trait is this Sickle Cell Trait Toolkit. It was jointly created by the Centers for Disease Control and Prevention, the American Society of Hematology and SCDAA.  

New Publications Emphasize Inequities in Pediatric SCD Care

This week, two new publications call attention to the barriers to care children with SCD face. Prioritizing Sickle Cell Disease, an article co-authored by SCDAA Chief Medical Officer Lewis Hsu for the American Academy of Pediatrics, is a call to action within the medical community to work together to maximize available screenings and treatments. The Centers for Disease Control and Prevention’s newly released Vital Signs publication, Preventing Sickle Cell Anemia Complications in Children, reports fewer than 50% of children 2-16 years old received the recommended screening for stroke in 2019. Both publications identify racism and discrimination as barriers to quality care and potentially lifesaving preventative measures for children with SCD.

Click here to read Prioritizing Sickle Cell Disease.

Click here to read Preventing Sickle Cell Anemia Complications in Children.  

MARAC Advisory Statement: Immunizations

August is National Immunization Awareness Month. What does that mean for individuals with sickle cell disease (SCD)?

The Big Picture from SCDAA MARAC
Individuals with sickle cell disease are more likely to have complications from many infections and receive a lot of benefit from immunizations. Family members can help protect a child or adult with sickle cell disease by also getting immunizations.

More Information
Immunizations and vaccines protect people from serious disease. The possible risks from a vaccine are much smaller than the possible bad outcomes from the diseases.

Streptococcus Pneumoniae

  • Streptococcus pneumoniae bacteria was a leading cause of death for children with SCD.
  • Infection with Strep pneumo can move quickly from fever to extremely sick in the intensive care in just a few hours for children with SCD. Losing spleen function due to clogging of the spleen with sickle red blood cells is what makes Strep pneumo bacteria so dangerous for SCD patients.
  • Immunizations against Strep pneumo are important for every child, and extra immunizations are recommended for individuals with SCD: Pneumovax-23 and PCV20.

Monkeypox (MPV)

  • MARAC monitoring has not found any unusual monkeypox problems in individuals with sickle cell disease. If anybody hears of unusual events with monkeypox and sickle cell disease, please pass along this information to the SCDAA Chief Medical Officer Dr. Lewis Hsu at info@sicklecelldisease.org.
  • MARAC encourages anyone with symptoms of monkeypox (MPV) to see a health care provider to get tested. If you do not have access to a provider, visit findhealthcarecenter.hrsa.gov to get connected.
  • There is a vaccine available for those who are at highest risk. If you are experiencing any symptoms contact your health care provider, avoid close contact with others and take a break from sex, going out to bars, gyms, clubs and other events. Do not share personal items, wash your hands and clean shared surfaces regularly.

COVID-19

  • The latest data continues to show that SCD does have increased vulnerability to severe COVID.
  • COVID can trigger SCD symptoms like vaso-occlusive pain or sickle acute chest syndrome.
  • MARAC strongly urges everyone with SCD and their families to get vaccinated and get all recommended boosters. In addition, you should consider wearing a mask, avoiding crowds and standing at least six feet away from other people.
  • Do not attend social events if you have symptoms of COVID-19 or tested positive for COVID 5 days prior, even if you’re vaccinated.
  • If you do catch COVID, SCD is among the conditions eligible to receive treatments to reduce the risk of getting severe disease and hospitalization. Contact your health care provider.

Influenza (the Flu)

  • MARAC encourages everyone to get immunized against influenza, especially individuals with SCD and their family members.
  • Influenza can lead to severe illness in individuals with SCD. Influenza can trigger a vaso-occlusive painful event or acute chest syndrome. The risks of the immunizations are less than the risks of severe influenza disease.

Other diseases

  • Immunizations against meningitis are very important in all individuals living with sickle cell disease.
  • Children with sickle cell should all be immunized following the recommendations of the CDC and American Academy of Pediatrics. Childhood immunizations can help protect against diseases that are deadly or disabling, like measles, polio, mumps, whooping cough or rubella.
  • There is currently an outbreak of Polio in communities with low rates of polio immunizations. Polio can cause permanent paralysis.
  • In tropical areas with malaria, avoid mosquito bites and take anti-malarial medicines, especially young children with SCD. Malaria immunizations began to be offered in 2021.
  • The risks of the immunizations are much smaller than the risks of these severe diseases.

Click here to download this MARAC statement.

Tools for Sickle Cell Awareness Month You Don’t Want to Miss

Member Organization Sickle Cell Awareness Month Events 2022

Join an SCDAA member organization at one of these great events this September!

 

Urge Officials to Cosponsor the SCD Comprehensive Care Act

Dear Sickle Cell Community,

Over the past several months, SCDAA has been working with congressional sickle cell disease (SCD) champions and other community and provider groups to advance bipartisan legislation to improve care for individuals with SCD. The Sickle Cell Disease Comprehensive Care Act (H.R. 6216 / S. 3389) authorizes the Centers for Medicare and Medicaid Services (CMS) to create a demonstration program to improve preventive and primary outpatient care for individuals living with SCD who are enrolled in Medicaid.

Members of Congress are back home for the August congressional district work period. Upon their return to Washington in September there will be a limited number of legislative workdays remaining before the November elections. Additional cosponsors are needed to show congressional leaders there is strong support for the Sickle Cell Disease Comprehensive Care Act and for the legislation to be scheduled for a vote in the House and Senate.

NOW is the time to reach out and remind your elected officials that September is Sickle Cell Awareness month and urge them to support individuals with SCD and their families by cosponsoring this legislation. Please click Take Action below to send a message to your Senators and Representatives. Please make sure to include your relationship to SCD (e.g., individual with SCD, parent, loved one or friend of an individual with SCD) at the beginning of the letter and feel free to personalize the text.

Thank you for your help in making sure Congress hears from the sickle cell community!

CLICK HERE TO TAKE ACTION

Sincerely,

Sickle Cell Disease Association of America  

The Passing of Dr. Samir Ballas

SCDAA regrets to announce that Dr. Samir Ballas passed away on August 12. He was devoted to caring for adults with sickle cell in Philadelphia at Thomas Jefferson University. He made many significant contributions to clinical research on sickle cell pain and lab research on sickle cell shape changes. Read the letter from his daughter that describes his deep faith and lifelong commitment to help sickle cell disease here: https://bit.ly/DrBallas. Our thoughts are with his family at this difficult time.

 

MARAC Advisory Statement: Monkeypox

July 20 – The Sickle Cell Disease Association of America’s Medical and Research Advisory Committee (MARAC) is aware of the news about monkeypox and is monitoring the situation. Please follow advisories from organizations such as the Centers for Disease Control and Prevention to avoid close, skin-to-skin contact with individuals who have a rash that looks like monkeypox. Learn more from the CDC here and read the CDC monkeypox FAQs here.

This statement has been provided by members of the Sickle Cell Disease Association of America’s Medical and Research Advisory Committee.

Memorial Service for Dr. Kwaku Ohene-Frempong

Dr. Kwaku Ohene-Frempong, a visionary sickle cell doctor and advocate, passed away on May 7, 2022, at 76. A memorial service to honor his life has been planned for Saturday, June 25, in Accra, Ghana. The memorial will be livestreamed for the hundreds of community members who will be unable to attend the live event in Accra. Please click here to register.

A website has also been created to commemorate Dr. Ohene-Frempong’s memory. Click here to visit the site and learn more about the outstanding impact he had on so many lives.